JP2019532635A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532635A5
JP2019532635A5 JP2019515539A JP2019515539A JP2019532635A5 JP 2019532635 A5 JP2019532635 A5 JP 2019532635A5 JP 2019515539 A JP2019515539 A JP 2019515539A JP 2019515539 A JP2019515539 A JP 2019515539A JP 2019532635 A5 JP2019532635 A5 JP 2019532635A5
Authority
JP
Japan
Prior art keywords
msc
ido
composition
oncolytic virus
infected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019515539A
Other languages
English (en)
Japanese (ja)
Other versions
JP7358236B2 (ja
JP2019532635A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/052313 external-priority patent/WO2018053529A1/en
Publication of JP2019532635A publication Critical patent/JP2019532635A/ja
Publication of JP2019532635A5 publication Critical patent/JP2019532635A5/ja
Application granted granted Critical
Publication of JP7358236B2 publication Critical patent/JP7358236B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019515539A 2016-09-19 2017-09-19 腫瘍溶解性ウイルスを腫瘍に標的化する方法 Active JP7358236B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662396604P 2016-09-19 2016-09-19
US62/396,604 2016-09-19
PCT/US2017/052313 WO2018053529A1 (en) 2016-09-19 2017-09-19 Method of targeting oncolytic viruses to tumors

Publications (3)

Publication Number Publication Date
JP2019532635A JP2019532635A (ja) 2019-11-14
JP2019532635A5 true JP2019532635A5 (enExample) 2020-10-15
JP7358236B2 JP7358236B2 (ja) 2023-10-10

Family

ID=61619005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515539A Active JP7358236B2 (ja) 2016-09-19 2017-09-19 腫瘍溶解性ウイルスを腫瘍に標的化する方法

Country Status (5)

Country Link
US (2) US11607426B2 (enExample)
EP (2) EP4268838A3 (enExample)
JP (1) JP7358236B2 (enExample)
CA (1) CA3037333A1 (enExample)
WO (1) WO2018053529A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018372631B2 (en) 2017-11-22 2025-06-05 Mesoblast International Sarl Cellular compositions and methods of treatment I
AU2020325825B2 (en) * 2019-08-05 2026-02-05 Mesoblast International Sarl Cellular compositions comprising viral vectors and methods of treatment
KR102233568B1 (ko) * 2019-12-13 2021-03-30 주식회사 알바이오 항암 바이러스가 도입된 중간엽 줄기세포의 세포 생존능을 향상시키는 방법
WO2022034506A1 (en) * 2020-08-10 2022-02-17 Mesoblast International Sárl Cellular compositions and methods of treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52711B (sr) 2005-05-10 2013-08-30 Incyte Corporation Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih
US8685728B2 (en) * 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
JP2011518841A (ja) 2008-04-24 2011-06-30 ニューリンク ジェネティクス， インコーポレイテッド Ｉｄｏ阻害剤
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
US8597637B1 (en) * 2010-05-18 2013-12-03 Weidong Zhang Breast cancer therapy using an engineered respiratory syncytial virus
CA2895148C (en) * 2012-12-14 2023-02-28 Yufang Shi Methods modulating immunoregulatory effect of stem cells
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
RU2667509C2 (ru) 2013-03-14 2018-09-21 Ньюлинк Джинетикс Корпорейшин Трициклические соединения в качестве ингибиторов иммуносупрессии, опосредуемой метаболизированием триптофана
US20160303174A1 (en) * 2013-12-11 2016-10-20 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors

Similar Documents

Publication Publication Date Title
Merten et al. Viral vectors for gene therapy and gene modification approaches
CN106659777A8 (zh) 免疫原性组合产品
JP2019532635A5 (enExample)
HRP20180282T1 (hr) Imunoterapija na bazi indoleamin 2, 3-dioksigenaze
WO2019040920A8 (en) PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS
WO2020028751A3 (en) Aav variants with enhanced tropism
EA201892648A1 (ru) Вирусы пичинде с трехсегментным геномом в качестве векторных вакцин
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
JP2014530010A5 (enExample)
EA201990718A1 (ru) Векторы аденовируса собачьих
JP2012136541A5 (enExample)
WO2008096831A1 (ja) 癌の治療剤
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
JP2014051497A5 (enExample)
JP2012126742A5 (enExample)
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
JP2015533376A5 (enExample)
WO2016100328A8 (en) Novel tilapia virus and uses thereof
JP2017524682A5 (enExample)
WO2008103380A3 (en) Hepatitis b virus compositions and methods of use
JP2016529223A5 (enExample)
JP2011528897A5 (enExample)
RU2019113989A (ru) Лекарственное средство
JP2014139185A5 (enExample)
WO2014140166A3 (en) Vaccine